Covishield
Hope to resolve soon: SII CEO Adar Poonawalla on Covishield-vaccinated Indians facing EU travel issues
Pune/IBNS: Serum Institute of India (SII) CEO Adar Poonawalla on Monday said he hopes to resolve the issues which Covishield-vaccinated Indians, who are planning to travel to Europe, are facing.
In a tweet, Poonawalla said, "I realise that a lot of Indians who have taken COVISHIELD are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries."
I realise that a lot of Indians who have taken COVISHIELD are facing issues with travel to the E.U., I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries.
— Adar Poonawalla (@adarpoonawalla) June 28, 2021
The SII manufactures the Oxford University's anti-COVID-19 vaccine AstraZeneca in India, named Covishield.
The European Union (EU) is planning to roll out from Jul 1 a new plan under which a "digital COVID certificate" will be introduced for travelling.
The certificate will be proof that the holder is vaccinated against the virus.
The EU's medical regulatory body has listed four anti-COVID-19 vaccines including AstraZeneca. However, Covishield does not feature in the list.
At present, only two vaccines, Covishield and indigenous Covaxin, have been rolled out in India.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
